NCT Number: NCT01987284
SER100 in Isolated Systolic Hypertension
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.
In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
FinnMedi Oy/Valkeakoski District Hospital, Tampere, Finland
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Mean systolic blood pressure ≥ 150 mmHg and mean diastolic blood pressure < 90 mmHg - as determined by daytime continuous ambulatory blood pressure measurement (ABPM)
- Male or female
- Age 50-80 years (both inclusive) at screening
- Patients must be on stable doses with one or more antihypertensives
- BMI <32 kg/m2
- Written informed consent
Exclusion criteria
- Acute myocardial infarction in the last 6 months before screening
- Stroke in the last 6 months before screening
- Uncompensated heart failure (NYHA Class IV)
- Angina pectoris with an anticipated need for administration of short-acting nitrates
- Known, severe sleep apnoea
- Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening
- Subjects working night shifts (11 PM to 7 AM)
- Participation in any other clinical trial with an investigational medicinal product or device within 1 month prior to randomisation.
- Subjects with upper arm circumference ≤24 cm or ≥ 42 cm.
- Any general condition, serious disease or current evidence of any mental or physical disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the judgment of the investigator makes the subject unsuitable for enrollment, and/or may interfere with the study evaluations or affect subject's safety and/or may cause risk for poor protocol compliance
- Pregnant or lactating women.
- Female subjects of childbearing potential, or male subjects whose female partner (unless post-menopausal for 1 year or surgically sterile) is unwilling to use adequate contraceptive measures throughout the duration of the study
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Number of participants with adverse events
Time frame: Up to 4 weeks
Secondary outcomes
-
Change from baseline in systolic blood pressure
Time frame: Up to 4 weeks
Sponsors and collaborators
Lead sponsor
Serodus AS
Industry
Collaborators
- Smerud Medical Research International AS
- The Research Council of Norway
Registry information
Official study title
A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Nov 19, 2013
- Registry last updated
- Oct 20, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Isolated Systolic Hypertension in the Elderly and Very Elderly
NCT00751829
Cardiovascular Diseases, Essential Hypertension
Munich, Germany
View Trial DetailsA Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
NCT01656408
Cardiovascular Diseases, Essential Hypertension
View Trial DetailsCardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
NCT05086523
Cardiovascular Diseases, Essential Hypertension
Prague, Czechia
View Trial DetailsPreload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06)
NCT04463121
Arrhythmias, Cardiac, Bradycardia
Prague, Czechia
View Trial Details